Prostate-specific antigen velocity in untreated, localized prostate cancer
β Scribed by Ramachandran Venkitaraman; Andrew Norman; Ruth Woode-Amissah; David Dearnaley; Alan Horwich; Robert Huddart; Chris Parker
- Book ID
- 109053540
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 140 KB
- Volume
- 0
- Category
- Article
- ISSN
- 1464-4096
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND. Increased preoperative prostateβspecific antigen (PSA) velocity (PSAV) has been associated with increased prostate cancer mortality and higher Gleason scores. The authors evaluated the relation between PSAV, biopsy Gleason score, and pathologic stage in men who were enro
The authors evaluated 440 men with clinically staged and untreated prostate cancer with a monoclonal prostate-specific antigen (PSA) assay. The serum PSA value correlated significantly with both the stage and grade of disease (P < 0.00005). The relationships between PSA and consecutive Stages A, B,
Prostate-specific antigen (PSA) is a wellcharacterized human prostate-specific glycoprotein. PSA has been shown to be the most effective immunohistologic marker for prostate cancer, as well as the most useful serologic test in staging and monitoring prostate cancer and in early detection of recurren